<DOC>
	<DOCNO>NCT01411436</DOCNO>
	<brief_summary>This study regulatory post-marketing surveillance Japan , local prospective observational study patient receive Nexavar unresectable hepatocellular carcinoma ( HCC ) . The objective study ass safety effectiveness Nexavar real-life practice condition . This study case investigation enrollment period 2 3 month ( dependent site ) Child-Pugh A ; Child-Pugh B C , enrollment continue agreement stop Pharmaceuticals Medical Devices Agency ( PMDA ) . All patient receive Nexavar recruit follow one year since start Nexavar administration .</brief_summary>
	<brief_title>Nexavar Post-marketing Surveillance Hepatocellular Carcinoma Japan</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Patients receive Nexavar unresectable hepatocellular carcinoma Patients contraindicate base product label</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Nexavar</keyword>
	<keyword>unresectable hepatocellular carcinoma</keyword>
</DOC>